ABSTRACT: Deregulation of ubiquitin conjugation or deconjugation has been implicated in the pathogenesis of many human diseases including cancer. The deubiquitinating enzyme USP1 (ubiquitin-specific protease 1), in association with UAF1 (USP1-associated factor 1), is a known regulator of DNA damage response and has been shown as a promising anticancer target. To further evaluate USP1/UAF1 as a therapeutic target, we conducted a quantitative high throughput screen of >400000 compounds and subsequent medicinal chemistry optimization of small molecules that inhibit the deubiquitinating activity of USP1/UAF1. Ultimately, these efforts led to the identification of ML323 (70) and related N-benzyl-2-phenylpyrimidin-4-amine derivatives, which possess nanomolar USP1/UAF1 inhibitory potency. Moreover, we demonstrate a strong correlation between compound IC 50 values for USP1/UAF1 inhibition and activity in nonsmall cell lung cancer cells, specifically increased monoubiquitinated PCNA (Ub-PCNA) levels and decreased cell survival. Our results establish the druggability of the USP1/ UAF1 deubiquitinase complex and its potential as a molecular target for anticancer therapies.
■ INTRODUCTION
Ubiquitin is a small, highly conserved protein of 76 amino acids that is post-translationally conjugated to substrate proteins, including itself, via a three-step enzymatic reaction. The initial covalent attachment primarily occurs between the C-terminal glycine of ubiquitin and the ε-amino group of lysine residue(s) of the target protein. 1 Additional ubiquitin molecules can be ligated to one of the seven internal lysines of ubiquitin, resulting in diverse ubiquitin chain topologies. The biological outcome of ubiquitination is determined by both the length and linkage topology. 2 For example, Lys48-linked polyubiquitin chains are almost exclusively associated with allocating proteins for proteasome-dependent degradation, while monoubiquitination or chains linked through different lysines have been shown to serve multiple nonproteolytic functions. 3−6 Similar to other types of post-translational modifications, ubiquitination is a reversible process counter-regulated by enzymes known as deubiquitinases (DUBs), which catalyze the removal of ubiquitin from modified proteins. 7 More importantly, dysfunction in ubiquitin-dependent signaling pathways has been linked to various human diseases, suggesting inhibition of ubiquitin pathway components as novel therapeutic targets for drug discovery.
Pharmacological intervention within the ubiquitin−proteasome system has been well established by the successful use of proteasome inhibitors for anticancer treatment. 8 Nevertheless, the ubiquitin−proteasome system offers additional opportunities for therapeutic intervention that could afford increased specificity and the possibility for improved clinical efficacy, which proteasome inhibitors are currently lacking. 9 The most apparent targets include enzymes involved in ubiquitin conjugation and deconjugation (i.e., ubiquitin ligases and DUBs), processes upstream of proteasome-mediated protein degradation. Among the DUBs, ubiquitin-specific protease 1 (USP1) has become an attractive anticancer target because of its involvement in regulating DNA damage response pathways. USP1 associates with UAF1 (USP1-associated factor 1), resulting in the heterodimeric USP1/UAF1 complex that is required for deubiquitinase activity. 10 The USP1/UAF1 complex has been shown to regulate the tolerance of DNA damage induced by DNA cross-linking agents through deubiquitination of PCNA (proliferating cell nuclear antigen) 11 and FANCD2 (Fanconi anemia complementation group D2), 12 which are proteins that function in translesion synthesis and the Fanconi anemia pathway, respectively. Williams et al. also recently reported that USP1/UAF1 deubiquitinates and prevents proteasomal degradation of ID (inhibitor of DNAbinding) proteins, 13 which have been shown to activate multiple pathways involved in tumor progression, including preservation of the cancer stem cell phenotype. 14 Moreover, evidence for aberrant overexpression of USP1 in several tumor types suggests that inhibitors of USP1 are likely to provide a therapeutic benefit. 13, 15 Several small-molecule inhibitors of USP1/UAF1 have been identified by high-throughput screening. We initially identified the first USP1/UAF1 inhibitors, pimozide and GW7647, from a collection of bioactive molecules. 16 Although GW7647 and pimozide display reasonable selectivity over related proteases and demonstrate cellular inhibition of human USP1, both compounds show moderate PubChem promiscuity with a 9.5% and 11.4% hit rate, respectively, and have annotated activity against unrelated targets.
17 −19 Since then, Mistry et al. reported C527 and related analogues, which exhibit submicromolar inhibition (IC 50 = 0.88 μM) of USP1/UAF1 activity, promote ID1 degradation, and cause cytotoxicity in several leukemic cell lines. 20 However, C527 displays limited selectivity for USP1/ UAF1 in vitro. We recently described the discovery and biological activity of ML323 (70) (Figure 1 ), a novel smallmolecule inhibitor of USP1/UAF1. Compound 70 was found to exhibit selective, nanomolar inhibition of USP1/UAF1 deubiquitinase activity, leading to an increase in monoubiquitinated forms of PCNA and FANCD2 and synergistic interaction with cisplatin in human tumor cell lines. 21 Herein, we describe the medicinal chemistry efforts that led to the selection of 70 as a chemical probe and provide biological activity and in vitro ADME data for additional analogues.
■ CHEMISTRY
To initiate our medicinal chemistry efforts, we began by resynthesizing the HTS hit molecule (1) , which was prepared as described in Scheme 1A/B. 21 The synthesis of related analogues (2−21) commenced with an EDC-mediated amide coupling between 2-aminobenzamide (i) and 2-9-(trifluoromethyl)benzoic acid as shown in Scheme 1A. 22 The resulting diamide was heated to reflux with sodium hydroxide for 3 h to provide the cyclized quinazoline scaffold, which upon treatment with POCl 3 gave the key intermediate 4-chloro-2-(2-(trifluoromethyl)phenyl)quinazoline (ii). This intermediate was then reacted with a variety of amines to provide analogues 2−21 (Table 1) . 23 Notably, compound 1 could also be synthesized in this manner using thiophen-2-ylmethanamine in step d.
The synthesis of analogues 22−53 and 71−75 were all achieved in a similar manner using (4-(pyridin-3-yl)phenyl)-methanamine for the amino side chain but differed in the dichloropyridimide-based scaffold starting material as shown in Scheme 1B. The preparation of analogues 22−36 involved addition of (4-(pyridin-3-yl)phenyl)methanamine to 2,4-dichloroquinazoline to obtain the desired chloropyridimide intermediate (iv) . Suzuki coupling of iv with various boronic acids using Pd(PPh 3 ) 4 in a microwave reactor for 30 min at 150°C gave analogues 22−33. For subsequent analogues, we changed to a silica bound DPP-palladium catalyst in order to alleviate any palladium contamination concerns. The synthesis of compounds 34−36 was conducted using the same sequence. However, instead of a Suzuki coupling, intermediate iv was heated in a sealed tube for 24 h at 100°C with an excess of requisite amine. The synthetic route for compounds 37−53 (Table 3) was performed as described above starting from other commercially available 2,4-dichloropyrimidine heterocycles, and 2-isopropylphenyl boronic acid was utilized in the cross coupling reaction.
Compounds 54−69 were synthesized using 2,4-dichloro-5-methylpyrimidine (v) as the starting material along with various commercially available heterocyclic and aromatic methanamines, followed by a Suzuki coupling with 2-isopropylphenyl boronic acid (Scheme 2). The tetrazole analogue (68) was obtained via reaction of the 4-CN-Ph moiety with sodium azide in DMF. Compounds 62−67 were synthesized by reacting commercially available tert-butyl 4-(aminomethyl)piperidine-1-carboxylate (for 62−65), tert-butyl-3-(aminomethyl)-pyrrolidine-1-carboxylate (for 67), or tert-butyl 3-(aminomethyl)azetidine-1-carboxylate (for 66), with 2,4-dichloro-5-methylpymidine, followed by the aforementioned Suzuki coupling conditions. The elevated temperatures used in the Suzuki coupling resulted in concomitant removal of the NBoc group to provide intermediates viii. Buchwald-Hartwig conditions for the cross coupling of the requisite amine and the heteroaryl bromides gave the desired products 63−67.
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Initially, we utilized the DavePhos ligand, however, this was met with limited success. Subsequent analysis of other ligands revealed that the RuPhos palladacycle proved optimal for compounds 63−64, whereas compounds 65−67 worked best with DavePhos. Oxetane analogue (62) was obtained via a reductive amination of intermediate viii (n = 2) and commercially available oxetan-3-one, with sodium triacetoxyborohydride.
Compounds 70 (ML323, Table 4 ) and 76−84 (Table 5) , were synthesized starting with 4-amino-benzonitrile as a TFA salt, trimethylsilyl azide, and t-butyl nitrite at 0°C to give the desired azide in 98% yield (Scheme 3). 26 The resulting azide was dissolved in a mixture of DMSO/H 2 O, treated with copper sulfate, ethynyltrimethylsilane, sodium ascorbate, and heated for 24 h at 80°C to give the desired 1,2,3-triazole. For the synthesis of the deuterated benzyl amine derivatives, we initially tried using the H-Cube flow-reactor with D 2 O but incomplete reduction and deuterium enrichment was observed. As such, the reduction was then carried out with lithium aluminum deuteride (LAD) to give the desired product in moderate yield (40%). 27 Our initial attempts for the nitrile reduction on the H- Cube with a 70 mm Catcart (10% Pd/C) at 50°C and 40 bar returned just trace amounts of product. However, the addition of TFA and changing to a MeOH/DMF mixture resulted in complete conversion to the amine (by LC-MS analysis). Given the water solubility of the 4-triazole-benzyl amine intermediates (x), it was used directly in the next step without further purification or characterization. The resulting mixture was heated for 18 h with 2,4-dichloro-5-methylpyrimidine and Et 3 N to give derivative xi in moderate yields of (∼40%) over the two steps. Compound xi was then coupled to the 2-isopropylphenyl boronic acid as described previously to give the final compound 70. Compounds 76−84 were synthesized as described above, however, several of the required boronic acids were not commercially available and had to be synthesized separately. For the deuterated analogues 80−82 and 84, the requisite d 6 and d 7 -2-isopropylphenyl boronic acids were prepared in four steps starting from 2-bromoacetophenone (see Supporting Information for details).
The synthesis of the oxetane containing analogues 72 and 77 involved preparation of 3-(2-bromophenyl)oxetane (xii) using a method described by Jacobsen et al. for a comparable phenyl oxetane derivative. 28 Formation of the (2-(oxetan-3-yl)phenyl)-boronic acid (xiii) was achieved in situ via treatment of xii with N-butyllithium and triisopropyl borate in THF at −78°C and subsequently used as-is with vi or xi to provide compounds 72 and 77, respectively (Scheme 4).
■ RESULTS AND DISCUSSION
After resynthesis of the thiophene-containing HTS hit (1) and confirmation of its activity in both the primary Ub-rhodamine qHTS assay and orthogonal gel-based diubiquitin assay, we decided to focus our initial SAR exploration efforts around the thiophene moiety (northern portion). Despite the modest activity against USP1/UAF1 (Table 1 ; IC 50 = 7.9 μM), we were encouraged by the selectivity of this compound, with no significant activity against a small panel of DUBs and appreciable inhibition of only one of 451 kinases. 21 Initial changes to the thiophene functionality were generally well tolerated, with only slight changes in potency being observed. Replacing the thiophene moiety with a simple phenyl ring (3) led to a modest improvement in potency (3.1 μM), however, most substituted (electron-withdrawing and electron-donating groups) phenyl rings (analogues 4−10) demonstrated fairly flat SAR. We were encouraged that substitution at the 4-position with a phenyl ring (e.g., 4-phenyl benzyl amine 12) was well tolerated with a comparable IC 50 value of 3.7 μM. This allowed for a variety of different analogues to be synthesized with representative examples (analogues 13−21) shown in Table 1 . Potencies approached 1 μM with both the 4-pyridine (16) and 3-pyridine (17) with IC 50 values of 1.9 and 1.1 μM, respectively. Given the comparable potency of these two analogues and the propensity of 4-pyridine derivatives to interact with CYPs, we decided to proceed with the 3-pyridine group for the next round of analogues which were aimed at modifying the 2-CF 3 -phenyl group and to investigate core scaffold changes.
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Exploration of the SAR around the 2-CF 3 -phenyl group indicated that substitution at the 2-position was greatly favored compared to the 3-and 4-positions ( Table 2 ). This finding is exemplified by the inactivity of the 3-CF 3 -phenyl (22) and 4-CF 3 -phenyl (23) derivatives. Given these results, we decided to focus on exploring SAR at the 2-position by replacing the CF 3 group with various electron-donating/withdrawing groups as well as varying the steric bulk in this portion of the molecule. Incorporation of the electron-withdrawing group; e.g., 2-NO 2 (24) led to a 7-fold loss in activity, whereas the electrondonating group, e.g., 2-OMe (25), provided comparable activity (IC 50 = 0.94 μM). Replacement with the simple alkyl substituents (R = 2-Me, 26 or R = 2-Et, 27) also provided comparable activity to the 2-CF 3 group. Our biggest potency improvement (6-fold) occurred when we replaced the 2-CF 3 with an isopropyl group (28), which had an IC 50 of 180 nM. Changing the methyl groups of the isopropyl moiety to fluoro groups (29) led to an appreciable decrease in potency. Other electron-withdrawing groups were prepared (analogues 30− 32), yet none of these had improved activity. Finally, modification of the phenyl ring to a cyclopentyl group (33) or nitrogen containing heterocycles (34−36) resulted in inactive compounds. Having already improved the potency over the original HTS hit compound 1 from 4.7 to 0.18 μM (26-fold), we decided to turn our attention toward modification of the quinazoline core.
Initial data from analogues in our qHTS collection suggested that replacement of the quinazoline core with a pyrimidine would be tolerated. This change would be beneficial in that it would reduce the molecular weight and lipophilicity of the lead compound. Gratifyingly, this modification was in fact tolerated and resulted in a compound with comparable potency (37, Table 3 ). Introduction of a 5-methyl group (38) resulted in a ∼2-fold increase in potency with an IC 50 value of 70 nM. Interestingly, moving the methyl group to the 6-position (39) resulted in a 3-fold decrease in potency (210 nM). The 5,6-dimethyl derivative (40) was also well tolerated as was the cyclopentylpyrimidine analogue 45, with IC 50 values of 120 and 160 nM, respectively. Incorporation of other heteroaromatic core scaffolds (41−44 and 46−48) provided compounds with good potency, with the most potent being the furan derivative 48. Other groups such as OMe (49), F (50), NH 2 (51), NMe 2 (52), and SMe (53) provided good potency with IC 50 values of 70, 110, 310, 190, and 110 nM, respectively. However, as stated above, our interest in these structural modifications was to improve or maintain potency while reducing molecular weight. Therefore, we decided to continue our SAR explorations with the 5-methyl-pyridimine (38) as the core scaffold given the potent inhibition (70 nM) and reduced size.
Having established the 5-methyl pyrimidine core and the 2-isopropyl group as optimal, we then decided to return to exploration of the "northern portion" SAR. Despite the potency of the terminal 3-pyridine group, some initial ADME data suggested that this group may be a metabolic liability. Replacement of the 4-(3-pyridine)-benzyl amine with a simple 3-methyl-phenyl (54), 3-pyridine (55), or thiophene (56) generally showed good potency in the Ub-Rho assay (130, 1300, and 270 nM, respectively), however, none of these had comparable potency to 38 in the orthogonal diubiquitin assay (data not shown). In an attempt to increase the hydrophilicity of the compound, a branched hydroxymethyl group (57) was introduced; however, this led to a large decrease in potency. Replacement of the phenyl group with an N-Me-piperidine (58) led to complete loss of activity. Given these data, we returned our focus to the two ring analogues (59−70). Adding a fluoro (59) or methyl (60) group, α to the pyridine nitrogen, was well tolerated (59, IC 50 = 80 nM; 60, IC 50 = 50 nM), which could help alleviate potential CYP interactions if necessary. However, these changes increase lipophilicity, which is something we were trying to avoid if possible. Looking to increase the sp 3 character of this side chain, we replaced the central phenyl group with a piperidine (analogues 62−65), which generally resulted in comparable potency with exception of oxetane derivative 62. However, the corresponding fourmembered (66) and five-membered (67) rings resulted in a loss of potency with IC 50 values of 21.7 and 0.8 μM, respectively. These data seem to indicate a size preference for six-membered ring with the potency rank order being phenyl ≈ piperidine > pyrollidine ≫ azetidine. In an attempt to attenuate the potential metabolic liability of the 3-pyridine moiety, several other nitrogen containing heterocycles were prepared and tested (analogues 68−70). The imidazole derivative (69) demonstrated moderate potency (300 nM), whereas the tetrazole (68) resulted in a significant decrease in potency. The latter result is unsurprising given the pK a differences in these heterocycles and the general preference for basic moieties in this position (e.g., pyridine). However, we were particularly intrigued by the 1,2,3-triazole derivative (70, IC 50 = 76 nM), given its improved metabolic stability, cell permeability, and activity in other biological assays (vide infra). 21 Compound 70 demonstrated modest metabolic stability (T 1/2 = 15 min) as shown in Table 5 , and Met ID studies (see Supporting Information, Figure S1 ) indicated that the two major metabolites involving oxidative removal of the N-benzyl group and hydroxylation of the isopropyl group. As such, in an effort to improve the half-life we first focused on the benzylic position and synthesized gem-dimethyl analogues 79 and 82 and deuterated analogues 83 and 84. Direct hydrogen abstraction is thought to be the rate-limiting step for CYPmediated hydroxylation of aliphatic compounds, and C−H bond cleavage is approximately 6−10 times faster than the corresponding C−D bond (kinetic isotope effect). 29, 30 Thus, replacement of metabolically labile hydrogen atoms with deuterium has been an attractive concept in drug discovery, as the change should have a negligible effect on the physicochemical properties yet improve metabolic stability. 10 Accordingly, we sought to utilize this strategy at both the benzylic position and 2-isopropyl moiety in effort to obviate metabolic instability. We thought this approach was particularly attractive for the 2-isopropyl group because our SAR efforts revealed this to be critical for activity and not easily replaced. Unfortunately, despite thorough investigation of various deuterated analogues (80−84), we did not notice any appreciable improvement in the metabolic half-life of this series. Analogue 79, which possesses the gem-dimethyl group, did show a moderate improvement in our studies, however, it remained below the desired stability of >30 min. In an attempt to address the undesired aliphatic hydroxylation at isopropyl group, we synthesized the cyclopropyl (71), cyclobutyl (76), oxetane (72 and 77), and difluoro (78) derivatives. While the cyclopropyl (71) and cyclobutyl (76) analogues demonstrated potent inhibition (IC 50 = 180 nM), the metabolic stability was not improved, with T 1/2 = 6.2 and 5.1 min, respectively. Replacement of lipophilic moieties with an oxetane group has been shown to improve the metabolic stability and solubility of the parent compound. 31 Interestingly, this result was realized in our case, as both oxetane derivatives (72 and 77) had favorable metabolic stability (T 1/2 > 30 min) and solubility (data not shown), however, they had lost all activity toward USP1/UAF1. While disappointed by this result, we decided to use compound 77 as our inactive control in subsequent biological studies, making it a vital analogue. The preference for having lipophilic moieties at the 2-position of the phenyl ring was further solidified with the testing of the alcohol (73−74) and ketone (75) analogues, which exhibited potencies in the micromolar range.
Our detailed SAR explorations around compound 1 led to a sufficient understanding of the structural features that are required for USP1/UAF1 inhibition. Thus, we sought to further evaluate the cellular activity of a number of selected compounds. We initially assessed the ability of the compounds to modulate USP1/UAF1 activity in cells by monitoring the level of monoubiquitinated PCNA (Ub-PCNA). Upon treatment of H1299 nonsmall cell lung cancer cells with select compounds (1, 64, 70, and 77), we observed a dose-dependent increase in Ub-PCNA compared to both the untreated control and the inactive oxetane analogue (77) (see Supporting Information, Figure S2 ). Importantly, an increase in Ub-PCNA was observed at concentrations as low as 1 μM for top compounds (e.g., 64 and 70). To ensure that a robust increase in Ub-PCNA was observed, additional compounds were tested at a fixed concentration of 20 μM. As shown in Figure 2A ,B, several compounds significantly increased the level of Ub-PCNA. More importantly, we observed a linear correlation between the logarithm of IC 50 values obtained in the HTS assay and fold change in Ub-PCNA (R 2 = 0.98, Figure 2C ). In addition to validating the reliability of the HTS assay, these results further support the on-target effects of this compound series in preventing the USP1/UAF1-catalyzed deubiquitination of PCNA in human cells. 21 We next examined the effects of these compounds on cell survival using a colony formation assay. As shown in Figure 3A , several of the compounds markedly inhibited the colonyforming capacity of H1299 cells relative to DMSO-treated control. Five compounds (48, 49, 64, 69, and 70) caused greater than 70% reduction of colony formation at 5 μM, whereas the original HTS hit (1) and the inactive oxetane analogue (77) had minimal or no effect on cell survival, respectively. A direct correlation between IC 50 values for USP1/UAF1 inhibition and cell survival was identified (R 2 = 0.93, Figure 3B ). As anticipated, the fold change in Ub-PCNA also correlated with cell survival (R 2 = 0.91, Figure 3C ), suggesting PCNA monoubiquitination as a candidate pharmacodynamic biomarker predictive of efficacy. Compound 70 was further evaluated in dose−response and demonstrated to have an EC 50 of 3.0 μM, while the inactive analogue 77 had no effect on cell survival up to 25 μM ( Figure 3D ). These results suggest that USP1/UAF1 inhibitors could show promise as a monotherapy despite being initially envisioned as a combination therapy with DNA damaging agents. 16, 21, 32 In Vitro ADME Profile. Having already evaluated the selectivity of this molecule against numerous DUBs, human proteases, and kinases, 21 we next wanted to determine ancillary pharmacology against GPCR and ion channel and transporter targets. To do so, we tested compound 70 at 10 μM in the CEREP LeadProfilingScreen2, which contains 80 different GRCRs, ion channels, and transporters. Once again, compound 70 demonstrated an encouraging selectivity profile, with only 7 targets showing inhibition of >50% at 10 μM (5-HT 2A , 2B , 2C , A 3 , Ca 2+ channel, MT 1 , and PPARγ) (see Supporting Information, Figure S4 ). A selection of the in vitro ADME attributes of compound 70 is highlighted in Table 6 . Notably, compound 70 possesses good kinetic solubility in PBS buffer (pH 7.4) of 86 μM, and the experimental Log D (pH 7.4) of 1.97 is well within the ideal range for orally bioavailable drug-like molecules. This value was obtained by Analiza Inc. using their "scaled-down shake flask lipophilicity" method. As anticipated, compound 70 is stable in PBS buffer, assay buffer, pH 2, pH 9 (see Supporting Information, Figure S3 , and mouse plasma (Table 6 ). Compound 70 also exhibits excellent Caco-2 permeability [P app = 23 (10 −6 cm/s)] and shows no signs of efflux (ratio = 0.9), which seems to indicate the compound is not subject to the action of transporters, such as Pgp. One remaining liability is the less than optimal microsomal stability, with an observed T 1/2 of 15 min (rat and mouse liver microsomes) and 26 min (human liver microsome). While our efforts to improve this liability have thus far been met with limited success, we fully expect that through further medicinal chemistry optimization this metabolic liability can be attenuated. Finally, preliminary in vivo PK studies of this compound indicate favorable bioavailability (>80%) yet rapid clearance (>70 mL/min/kg), which is likely a result of the marginal phase I metabolic stability discussed above.
■ CONCLUSION
DUBs have been implicated in cancer and other human diseases and thus have become increasingly regarded as prospective targets for therapeutic intervention. 33−35 Here, we summarize the medicinal chemistry optimization efforts of a series of N-benzyl-2-phenylpyrimidin-4-amine based USP1/ UAF1 deubiquitinase inhibitors. We succeeded in generating several inhibitors with nanomolar potency, which corresponds to ≥100-fold improved activity compared to the original HTS hit (1) . In addition, we demonstrate activity in cells with selected compounds as single agents, specifically increasing the level of monoubiquitinated-PCNA and decreasing cell survival in nonsmall cell lung cancer cells (Figure 2 and 3) . It has recently been demonstrated that small-molecule inhibitors of USP1/UAF1 are cytotoxic to both established leukemic cell lines and patient-derived leukemic cells. 20 The data presented here also supports the use of USP1/UAF1 inhibitors as a monotherapy in nonsmall cell lung cancer (Figure 3 ). In addition to further medicinal chemistry optimization to improve ADME properties, we are currently attempting to identify cancer subtypes or patient populations that may benefit from USP1/UAF1-targeted therapy.
■ EXPERIMENTAL SECTION
General Chemistry Methods. All air or moisture sensitive reactions were performed under positive pressure of nitrogen with oven-dried glassware. Chemical reagents and anhydrous solvents were obtained from commercial sources and used as-is. Preparative purification was performed on a Waters semipreparative HPLC. The column used was a Phenomenex Luna C18 (5 μm, 30 mm × 75 mm) at a flow rate of 45 mL/min. The mobile phase consisted of acetonitrile and water (each containing 0.1% trifluoroacetic acid). A gradient of 10−50% acetonitrile over 8 min was used during the purification. Fraction collection was triggered by UV detection (220 nm). Analytical analysis for purity was determined by two different methods denoted as final QC methods 1 and 2. Method 1: Analysis was performed on an Agilent 1290 Infinity series HPLC UHPLC long gradient equivalent 4−100% acetonitrile (0.05% trifluoroacetic acid) in water over 3.5 min run time of 4 min with a flow rate of 0.8 mL/min. A Phenomenex Kinetex 1.7 μm C18 column (2.1 mm × 100 mm) was used at a temperature of 50°C. Method 2: Analysis was performed on an Agilent 1260 with a 7 min gradient of 4−100% acetonitrile (containing 0.025% trifluoroacetic acid) in water (containing 0.05% trifluoroacetic acid) over 8 min run time at a flow rate of 1 mL/min. A Phenomenex Luna C18 column (3 μm, 3 mm × 75 mm) was used at a temperature of 50°C. Purity determination was performed using an Agilent diode array detector for both method 1 and method 2. Mass determination was performed using an Agilent 6130 mass spectrometer with electrospray ionization in the positive mode. All of the analogues for assay have purity greater than 95% based on both analytical methods.
1 H and 13 C NMR spectra were recorded on a Varian 400 (100) MHz spectrometer. High resolution mass spectrometry was recorded on Agilent 6210 time-of-flight LC-MS system. N-(Thiophen-2-ylmethyl)-2-(2-(trifluoromethyl)phenyl)-quinazolin-4-amine (1). 21 2,4-Dichloroquinazoline (0.50 g, 2.51 mmol), thiophen-2-ylmethanamine (0.34 g, 3.0 mmol), and triethylamine (Et 3 N) (1.0 mL, 7.54 mmol) was stirred overnight in CH 2 Cl 2 (6.0 mL) at room temperature. The reaction mixture was poured into water and extracted (3×) with CH 2 Cl 2 , and the organic layers were combined, washed (1×) with brine, dried over Na 2 SO 4 , filtered, and concentrated to provide 2-chloro-N-(thiophen-2-ylmethyl)quinazolin-4-amine, which was used without further purification in the next reaction. LC-MS retention time (method 1) = 3.334 min.
A 5 mL microwave reaction vessel was charged with a mixture of the above-mentioned 2-chloro-N-(thiophen-2-ylmethyl)quinazolin-4-amine (0.09 g, 0.31 mmol), 2-(trifluoromethyl)phenylboronic acid (0.18 g, 0.96 mmol), Pd(PPh 3 ) 4 (0.06 g, 0.05 mmol), sodium carbonate (0.40 M in water, 1.2 mL, 0.48 mmol), and acetonitrile (1.2 mL). The vessel was sealed and heated, with stirring, at 150°C for 10 min via microwave irradiation. The organic portion was concentrated under reduced pressure, and the residue was purified by silica gel chromatography using (80% hexanes, 20% ethyl acetate) to give the desired product. 1 01 (s, 3 H) . 13 (pyridin-3-yl) piperidin-4-yl)methyl)pyrimidin-4-amine (64). The synthetic method for compound 48 was followed and 2,4-dichloro-5-methylpyrimidine was substituted for 2,4-dichlorofuro[3,2-d]pyrimidine and tert-butyl 4-(aminomethyl)piperidine-1-carboxylate for (4-(pyridin-3-yl)-phenyl)methanamine to give the desired product. The cross coupling step removed the tert-butyl carbamate to give 2-(2-isopropylphenyl)-5-methyl-N-(piperidin-4-ylmethyl)pyrimidin-4-amine, which was purified on silica gel with CH 2 Cl 2 /MeOH(saturated with NH 3 ). LC-MS retention time (method 1): 2.538 min. This compound was used in the next step with no further characterization. To degassed xylene (5 mL), 2-(2-isopropylphenyl)-5-methyl-N-(piperidin-4-ylmethyl)-pyrimidin-4-amine (0.52 g, 1.60 mmol), 2′-(dicyclohexylphosphino)-N,N-dimethylbiphenyl-2-amine (DavePhos) (0.01 g, 0.02 mmol), sodium tert-butoxide (0.22 g, 1.4 mmol), Pd 2 (dba) 3 (0.02g, 0.02 mmol), and 3-bromopyridine (0.30 g, 1.92 mmol) were added and heated in a sealed tube to 100°C for 18 h. The reaction material was loaded directly onto silica gel and purified using (0−10% MeOH/ DCM). 
60 mmol) and potassium phthalimide (0.58 g, 3.1 mmol) were heated in DMF (2.5 mL) to 120°C for 18 h. The reaction mixture was cooled to 0°C, poured into water, and the solids were filtered and washed with water to give 2-(4-(1H-imidazol-1-yl)benzyl)-isoindoline-1,3-dione. The dried 2-(4-(1H-imidazol-1-yl)benzyl)-isoindoline-1,3-dione (0.40 g, 1.32 mmol) was heated to 95°C in a mixture of EtOH and hydrazine (4:1) for 1 h, the mixture was cooled, and the solids filtered. The solids were washed with EtOH to give (4-(1H-imidazol-1-yl)phenyl)methanamine. LC-MS retention time (method 1): 2.233 min. This material was used as-is in the synthesis of N-(4-(1H-imidazol-1-yl)benzyl)-2-chloro-5-methylpyrimidin-4-amine.
(4-(1H-Imidazol-1-yl)phenyl)methanamine 0.20 g, 1.17 mmol), 2,4-dichloro-5-methylpyrimidine (0.19 g, 1.17 mmol), and Et 3 N (0.33 mL, 2.34 mmol) in DMF (4 mL) were heated to 100°C for 18 h. The reaction mixture was monitored by LC-MS; when complete, the mixture was poured into water and extracted with ethyl acetate (3×), and the organic layers were combined, dried over Na 2 SO 4 , filtered, and concentrated to give the desired intermediate. LC-MS retention time (method 1): 2.460 min. The cross coupling used the method as described in compound 48, with a yield of 40%. 4-(1H-1,2,3-Triazol-1-yl)benzonitrile TFA (x). 21 4-Aminobenzonitrile (1.00 g, 8.46 mmol) and trifluoroacetic acid (TFA) (0.65 mL, 8.46 mmol) in acetonitrile (70 mL) were stirred at room temperature for 5 min. The reaction mixture was cooled to 0°C in a salt ice bath before the dropwise addition of tert-butyl nitrite (1.51 mL, 12.70 mmol), followed by azidotrimethylsilane (1.35 mL, 10.16 mmol). This reaction mixture was stirred for 30 min at 0°C and allowed to warm to room temperature (rt) before pouring into ethyl acetate (50 mL) and water (75 mL). The water layer was extracted (2×) with ethyl acetate, and the organic layers were combine and washed (1×) with brine. The combined organic layer was dried over Na 2 SO 4 , filtered, and concentrated under reduced pressure to give 1.22 g of the product as a reddish-brown solid. The compound was used as-is in the next reaction. LC-MS retention time (method 2:3 min) = 3.331 min.
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4-Azidobenzonitrile (1.22 g, 8.33 mmol), sodium ascorbate (1.32 g, 6.66 mmol), copper(II) sulfate (93 mg, 0.06 mmol), and ethynyltrimethylsilane (6.20 mL, 50.0 mmol) was heated in DMSO/ water (80 mL/40 mL) to 80°C in a sealed tube for 24 h. The reaction was allowed to cool to rt, poured into ethyl acetate, and washed (3×) with 100 mL of water. The combined organic layer was dried over Na 2 SO 4 , filtered, and concentrated under reduced pressure to give a pale-yellow residue. The residue was taken up in acetonitrile (16 mL) and TFA (0.64 mL, 8.33 mmol) and heated to reflux for 3 h. After this time, the reaction was cooled to rt and poured in to ethyl acetate (30 mL), washed (2×) with saturated sodium bicarbonate, dried over Na 2 SO 4 , filtered, and concentrated and placed on a reverse phase flash system for purification (gradient 20−100% acetonitrile w/0.1% TFA in water w/0.1% TFA). 1 N-(4-(1H-1,2,3-Triazol-1-yl)benzyl)-2-chloro-5-methylpyrimidin-4-amine TFA (xi). 21 4-(1H-1,2,3-Triazol-1-yl)benzonitrile (1.2 g, 7.05 mmol) and TFA (0.60 mL, 7.80 mmol) was dissolved in methanol (100 mL)/DMF (10 mL) and passed through a H-Cube Pro flow reactor using a 10% Pd/C 70 mm Catcart at 40 bar and 50°C. Once N-(4-(1H-1,2,3-Triazol-1-yl)benzyl)-5-methyl-2-(2-(oxetan-3-yl)-phenyl)pyrimidin-4-amine TFA (77). 21 3-(2-Bromophenyl)oxetane was synthesized using the method described by Jacobsen et. al, 23 except diethyl 2-(2-bromophenyl)malonate was used as the starting material instead of diethyl 2-(2-(benzyloxy)phenyl)malonate. This synthetic sequence was carried out without further purification/ characterization of the intermediates.
In an oven-dried 50 mL round-bottom flask, the above-mentioned 3-(2-bromophenyl)oxetane (0.14 g, 0.66 mmol) and THF (4 mL) was cooled to −78°C. The dropwise addition of N-butyllithium (0.85 mL, 1.36 mmol) by syringe occurred over a 15 min period. After this time, the reaction mixture was allowed to stir at −78°C for an additional 2 h. The contents were transferred via cannula to a second 50 mL ovendried round-bottom flask containing a stirred solution of tripropyl borate (0.29 mL, 1.32 mmol) and THF (2.0 mL) and cooled to −78°C
. Once transferred (by cannula), the mixture was allowed to stir at −78°C for 10 min, after which time the ice bath was removed and the reaction mixture stirred overnight. One N HCl was used to adjust the pH to ∼1, and the acidic mixture was stirred for 45 min, poured into water, and extracted with diethyl ether (3×). The organic layers were combined, dried over MgSO 4 , concentrated, and once the solvent was evaporated, a ∼1 M solution of the crude (2-(oxetan-3-yl)phenyl)-boronic acid in 1,2-DME was made and used in next step with no further purification. In a sealed tube N-(4-(1H-1,2,3-triazol-1-yl)benzyl)-2-chloro-5-methylpyrimidin-4-amine (0.10 g, 0.33 mmol) was combined with (2-oxetainphenyl)boronic acid as a 1 M solution in DME sodium carbonate (2.0 M in water, 0.33 mL, 0.67 mmol) and DPP-Pd Silicycle 0.26 mmol/g (0.20 g) in DME (2.0 mL), and heated at 150°C for 30 min in a Biotage Initiator microwave reactor. The resulting mixture was filtered over Celite and purified by reversedphase HPLC (gradient 20−100% acetonitrile w/0.1% TFA in water w/0.1% TFA) to give the desired product 77. concentrated, and used as in with no further purification or characterization. LC-MS retention time (method 1): 2.670 min. N-(2-(4-Aminophenyl)propan-2-yl)-2-(2-isopropylphenyl)-5-methylpyrimidin-4-amine (0.12 g, 0.33 mmol) and trifluoroacetic acid (TFA) (0.04 mL, 0.33 mmol) in acetonitrile (2 mL) was stirred at room temperature for 5 min. The reaction mixture was cooled to 0°C in an ice bath before the dropwise addition of tert-butyl nitrite (0.06 mL, 0.50 mmol) followed by azidotrimethylsilane (0.05 mL, 0.40 mmol). This mixture was stirred for 30 min at 0°C, allowed to warm to room temperature (rt), and poured into ethyl acetate (10 mL) and water (15 mL). The water layer was extracted with ethyl acetate (2×) and organic layers were combined and washed with brine (1×), dried over Na 2 SO 4 , filtered, and concentrated under reduced pressure to give to give the N-(2-(4-azidophenyl)propan-2-yl)-2-(2-isopropylphenyl)-5-methylpyrimidin-4-amine, which was used as-is in the next reaction without further purification. LC-MS retention time (method 1): 3.331 min. N-(2-(4-Azidophenyl)propan-2-yl)-2-(2-isopropylphenyl)-5-methylpyrimidin-4-amine (33 mg, 0.09 mmol), ethynyltrimethylsilane (0.13 mL, 1.03 mmol), sodium ascorbate (14 mg, 0.07 mmol), and copper(II)sulfate (1 mg, 0.006 mmol) in DMSO/H 2 O (1 mL/0.5 mL) was sealed in a tube and heated to 80°C for 24 h. the cooled reaction mixture was poured into water and extracted with ethyl acetate (3×), dried over Na 2 SO 4 , filtered, concentrated, and taken up in acetonitrile (3 mL) and TFA (0.11 mL, 0.92 mmol), heated to reflux for 3 h, then the reaction was cooled and concentrated under reduced pressure. This material was purified with reverse phase to give compound 79. Biological Methods. USP1/UAF1 Quantitative High-Throughput Screening Assay. USP1/UAF1 activity was monitored in a fluorometric ubiquitin−rhodamine110 assay as previously described. 16, 21 Western Blot. H1299 cells were seeded in 12-well plates at a density of 1 × 10 5 per well and allowed to attach overnight. Cells were treated with 20 μM of the indicated compounds or with an equal volume of DMSO for 4 h. Total protein extracts were prepared in RIPA lysis buffer (25 mM Tris-HCl (pH 7.6), 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS) containing protease and phosphatase inhibitor cocktail (Thermo Scientific). The concentration of protein lysates was determined using the Bio-Rad DC protein assay (Bio-Rad). Cell extracts were separated on 4−12% gradient SDS-PAGE and transferred to nitrocellulose. The membranes were blotted with PCNA antibody (PC10, Santa Cruz) or GAPDH antibody (D16H11, Cell Signaling), followed by incubation with HRP-conjugated antimouse or antirabbit secondary antibody, respectively. Blots were imaged using the Bio-Rad ChemiDocTM XRS gel imager and quantified using ImageQuant TL (GE).
Colony Formation Assay. H1299 cells were seeded in 6-well plates at a density of 200 cells per well and allowed to attach overnight. Cells were treated with 5 μM of the indicated compounds or with an equal volume of DMSO. Seven days after compound treatment, plates were fixed with 20% methanol and stained with 0.1% crystal violet. Plates were images with the Typhoon FLA 7000 (GE), and colonies were counted using ImageQuant TL (GE). Cell survival was expressed in percentage with DMSO-treated cells set as 100%.
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